Patent ID: 7479551
Filing Date: 2009-01-20
Classification: A61K,A61P,C07K,C12N

Abstract:
1. An isolated nucleic acid molecule, said nucleic acid molecule comprising a nucleic acid sequence encoding a mutant Factor VII (FVII) or mutant Factor VIIa (FVIIa) polypeptide, said mutant FVII or mutant FVIIa polypeptide comprising a modified γ-carboxyglutamic acid (GLA) domain that enhances membrane binding affinity of said mutant FVII or mutant FVIIa polypeptide relative to a wild type human Factor VII (hFVII) or wild type human Factor VIIa (hFVIIa) polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs from the amino acid sequence of the GLA domain of hFVII or hFVIIa polypeptide shown in SEQ ID NO:3 in 1 to 5 amino acid substitutions, wherein the proline residue at amino acid position 10 of SEQ ID NO:3 is substituted with a glutamine, aspartic acid or glutamic acid residue in the modified GLA domain, and wherein amino acid positions of the amino acid sequence of the modified GLA domain are numbered according to SEQ ID NO:3.